DocumentsDate added
Case report
Cemil Kavalci1,*, Meliha Findik1, Elif Kilicli1, Gulsum Kavalci2, Polat Durukan3
Affiliation:-
1Baskent University Faculty of Medicine, Emergency Department, Ankara, Turkey
2Yenimalle State Hospital, Anesthesia Department, Ankara, Turkey
3Erciyes University Faculty of Medicine, Emergency Department, Kayseri, Turkey
The name of the department(s) and institution(s) to which the work should be attributed:
1.Baskent University Faculty of Medicine, Emergency Department, Ankara, Turkey
2.Yenimalle State Hospital, Anesthesia Department, Ankara, Turkey
3.Erciyes University Faculty of Medicine, Emergency Department, Kayseri, Turkey
Address reprint requests to
Cemil Kavalci,
Associate Professor,
Baskent University Faculty of Medicine, Emergency Department, 06370 Ankara, Turkey
Article citation: Kavalci C , Findik M, Kilicli E, Kavalci G, Durukan P. Intravesical foreign body: Silicone. J Pharm Biomed Sci. 2014; 04(11):941-942. Available at www.jpbms.info
ABSTRACT
Intravesical foreign bodies are rarely seen. Forty-two year old male patient was admitted to the emergency room with complaints of inability to urinate for one day. Tubular foreign body in the bladder was detected on ultrasonography. About 30 cm long and 20 French thick silicone foreign body was removed from the bladder by cystoscopy.
KEYWORDS: Emergency; bladder; foreign body.
REFERENCES
1. Bello JO, Badmus KO, Babata AL, Bello HS. Polyembolokoilamania: Self-insertion of transistor radio antenna in male urethra. Niger Med J. 2013;54:206-8. doi: 10.4103/0300-1652.114578.
2. Datta B, Ghosh M, Biswas S. Foreign Bodies in Urinary Bladders. Saudi J Kidney Dis Transpl 2011;22:302-5,
3. Fikri O, Ozkan A, Kurtuluş OF, Bahadır M, Balcı C, Hazar Aİ, Nuhoglu B. Foreign Body in Bladder of a Patient with Urethral Stenosis: A Case Report. JAREM 2012;2:82-84.
ACKNOWLEDGEMENT
This study presented on 1. İntercontinental Emergency Medicine Congress, 15-18 May 2014, Turkey.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © Kavalci C, Findik M, Kilicli E, Kavalci C, Durukan P. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Vijay Mahantesh Sunkad1,*, Vijaya Mahanth Prasad.K2, Chethana. KV3
Affiliation:-
1,2Senior Resident, Department of Orthopedics,3Post Graduate, Department of Community Medicine, Navodaya Medical College Hospital, Raichur, Karnataka,India
The name of the department(s) and institution(s) to which the work should be attributed:
Navodaya Medical College Hospital, Raichur, Karnataka,India
Address reprint requests to
Dr.Vijay Mahantesh Sunkad
Senior Resident, Department of Orthopedics, Navodaya Medical College Hospital, Raichur, Karnataka, India
Article citation: Sunkad VM,Prasad VM,Chethana KV. Functional outcome of tibial plateau fractures treated with open reduction and internal fixation. J Pharm Biomed Sci. 2014; 04(11):959-966. Available at www.jpbms.info
ABSTRACT
Background: Tremendous advance in mechanization and the fastness of travel has been accompanied by a steep increase in the number and severity of fractures and those of tibial plateau are no exception. This study is to analyze the functional outcome of CRIF or ORIF with or without bone grafting in tibial plateau fractures in adults.
Methods: 30 Cases of tibial plateau fractures treated by various modalities were studied from 10-05-2011 to 30-05-2012 at our hospital and followed for a minimum of 6 months.
Results: Immobilization of fractures continued for 3 weeks by POP slab. Early range of motion was then started. Weight bearing up to 6-8 weeks was not allowed. The full weight bearing deferred until 12 weeks or complete fracture union. The knee range of motion was excellent to very good, gait and weight bearing after the complete union was satisfactory, knee stiffness in 3 cases, wound dehiscence and infection in 1 case and non-union in none of our cases was noted.
Conclusion: Functional outcome is better in operatively treated tibial plateau fractures in adults, because it gives an excellent anatomical reduction and rigid fixation to restore articular congruity and early motion thereby preventing knee stiffness.
KEYWORDS: Tibial plateau fractures; Schatzkar classification; Open reduction and internal fixation; closed reduction and internal fixation.
REFERENCES
1.Whittle AP and Wood II GW. Fractures of lower extremity chapter 51 in Compbells operative Orthopaedics Canale ST Ed; 10th edn. Vol.3; New York, Mosby 2003; 2782-2796.
2.Watson JJ and Wiss AD. Fractures of the proximal tibia and fibula, chapter 44 in Rockwood and Green’s fractures in adults, Bucholz RW and Heckman JD Ed. 5th ed. Vol 2: Philadelphia, Lippincott Williams and Wilkins 2001; 1799-1839.
3.Rassmussen P.S: Tibial condylar fractures. Impairment of knee joint stability as an indication for surgical treatment. J Bone and Joint Surg., 55-Am 1331-1350, Oct 1973.
4.Honkonen SE. Indications for surgical treatment of tibial condyle fractures. Clin Orthop 1994; 302: 199-205.
5.Schatzkar J, Mc Broom R and Bruce D. The tibial plateau fractures–Toronto experience. Clin Orthop, 1979; 138:94.
6.Bennett WF and Browner B. Tibial plateau fractures- a study of associated soft tissue injury. J.Ortho.Trauma 1992;6: 78.
7.Ebraheim NA, Sabry FF, Haman SP. Open reduction and internal fixation of 117 tibial plataru gtsvyutrd. Zotyhoprfiv 2004; 27(12): 1281.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © Sunkad VM, Prasad VM, Chethana KV. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
Original article
Shanta Nibedita Satpathy*
Affiliation:-
Associate Professor, Department of ENT, Hi-Tech Medical College, Bhubaneswar, Odisha, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of ENT, INHS Ashwini, Colaba Mumbai, Maharastra, India
Address reprint requests to
Dr. Shanta Nibedita Satpathy.
Department of ENT, Hi-Tech Medical College, Bhubaneswar, Odisha, India
Article citation:
Satpathy SN. Role of Immunotherapy: Histaglobulin in Allergic Rhinitis. J Pharm Biomed Sci. 2014; 04(11):967-971. Available at www.jpbms.info
ABSTRACT
Objective: The aim of our study was to improve the quality of life of Allergic Rhinitis patients by giving Histaglobulin injection. Otolaryngologists have been disappointed with the results of various modalities available for the treatment of allergic rhinitis. This problem can be solved with Histaglobulin.
Materials and methods: A study of 50 patients of allergic rhinitis in South Bombay was conducted in the department of ENT and Head and Neck Surgery in INHS Ashwini at Colaba for a period of 18 months. Histaglobulin was administered by subcutaneous injection in doses of 2 cc once a week for 3weeks and follow up was done for 40 weeks.
Results: The effectiveness of Histaglobulin was evaluated by detail history of clinical examination to assess the response to therapy. Twenty three (23) patients had complete response; twenty five (25) had fair response while two (2) patients had a poor response.
Conclusions: The results of Histaglobulin therapy was satisfactory. There was no adverse reaction following the therapy.
KEYWORDS: Allergic Rhinitis; Histaglobulin; Quality of Life.
REFERENCES
1.Parrot, J.L. Histaminolyse at histaminopesive: Actualities pharmacologiques 11th Ser PP. 233-257, Paris Masson 1958.
2.NormanPhilp S., Immunotherapy for nasal allergy, Journal of Allergy clinical Immunology pp.992-996, May 1988.
3.Gelfand, H. herald, cinder Jesus. Grant Sydney F. and Soiffer Maxwell: Evaluation of Histamine – Gammaglobulin in treatment of various allergic conditions, Annals of Allergy,1963;21:150-161.
4.Asokan N.N. and Sukumaran E.M., Gammaglobulin histamine complex in the treatment of allergic disorders of respiratory tract, the Indian Practitioner. 1982;35:171-176.
5.Borodin Y, Egerova Mezhcodava A, The use of Gammaglobulin and Histamine for treating Allergic disease, Rev. allergy ad appl. Immunology, 17.434, 1963.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussing research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Satpathy SN. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Review article
Mukund Joshi1,*, Kuldip Singh Sodhi2, Rajesh Pandey2, Jasbir Singh2, Subhash Goyal3
Affiliation:-
1(MSc Medical Biochemistry),Department of Biochemistry,MMIMSR, Mullana, Ambala, Haryana, India.
2Professor,Department of Biochemistry,MMIMSR, Mullana, Ambala, Haryana, India.
3Professor, Department of Surgery, MMIMSR, Mullana, Ambala, Haryana, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Biochemistry, MMIMSR, Mullana, Ambala, Haryana, India
Address reprint requests to
Mukund Joshi.
Department of Biochemistry,
MMIMSR, Mullana, Ambala, Haryana, India
Article citation:
Joshi M, Sodhi KS, Pandey R, Singh J, Goyal S. Serum uric acid and Cardiovascular disease. J Pharm Biomed Sci. 2014; 04(11):972-983. Available at www.jpbms.info
ABSTRACT
A substantial body of epidemiological and experimental evidence suggests the significance of serum uric acid as an important and independent risk factor of cardiovascular and renal diseases especially in patients with diabetes mellitus, hypertension or heart failure. Elevated serum uric acid is highly predictive of mortality in patients with heart failure or coronary artery disease and of cardiovascular events in patients with diabetes. Moreover patients with hypertension and hyperuricemia have a 3- to 5-fold increased risk of experiencing coronary artery disease or cerebrovascular disease compared with patients with normal uric acid levels. Although the mechanisms by which uric acid may play pathogenetic role in cardiovascular disease is unclear. Hyperuricemia is associated with deleterious effects on endothelial dysfunction, oxidative metabolism, platelet adhesiveness, hemorheology, and aggregation. Xanthine oxidase inhibitors (e.g., allopurinol) or a variety of uricosuric agents (e.g., probenecid, sulfinpyrazone, benzbromarone, and benziodarone) can lower elevated uric acid levels but it is unknown whether these agents reversibly impact cardiovascular outcomes. Hyperuricemia will become then a meaningful target for the prevention and treatment of cardiovascular disease. Overall, serum uric acid may be a powerful tool to help stratify risk for cardiovascular disease. At the very least, it should be carefully considered when evaluating overall cardiovascular risk.
KEYWORDS: Hypertension; uric acid; gout; allopurinol; coronary heart disease.
REFERENCES
1.Skak-Nielsen H. Torp-Pedersen C, Finer N, Caterson ID, Van Gaal L, James WP, et al. Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. PLoS One. 2013; 8(3): e59121.
2.Emmerson BT. The management of gout. N Engl J Med. 1996; 334(7): 445-51.
3.Steele TH. Hyperuricemic nephropathies. Nephron. 1999; 81(1): 45-9
4.Yeldandi AV, Patel YD, Liao M, Kao FT, Rao MS, Reddy JK, et al. Localization of the human urate oxidase gene (UOX) to 1p22. Cytogenet Cell Genet. 1992; 61(2): 121-2.
5.Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992; 34(1): 78-84.
6.Kohn PM, Prozan GB. Hyperuricemia; relationship to hypercholesteremia and acute myocardial infarction. J Am Med Assoc. 1959; 170(16): 1909-12.
7.Beard JT 2nd. Serum uric acid and coronary heart disease. Am Heart J. 1983; 106(2): 397-400.
8.Torun M, Yardim S, Simsek B, Burgaz S. Serum uric acid levels in cardiovascular diseases. J Clin Pharm Ther. 1998; 23(1): 25-9.
9.Waring WS, Webb DJ, Maxwell SR. Uric acid as a risk factor for cardiovascular disease. QJM. 2000a; 93(11): 707-13.
10.Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999; 34(1): 144-50.
11.Ward HJ. Uric acid as an independent risk factor in the treatment of hypertension. Lancet. 1998; 352(9129): 670-1.
12.Liese AD, Hense HW, Löwel H, Döring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology. 1999; 10(4): 391-7
13.Bengtsson C, Lapidus L, Stendahl C, Waldenström J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand. 1988; 224(6): 549-55
14.Lehto S, Niskanen L, Rönnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke. 1998; 29(3): 635-9.
15.Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart. 1997; 78(2): 147-53.
16.Coronaty heart project research group; Serum uric acid: its association with other risk factors and with mortality in coronary heart disease. J Chronic Dis. 1976; 29(9): 557-69.
17.Reunanen A, Takkunen H, Knekt P, Aromaa A. Hyperuricemia as a risk factor for cardiovascular mortality. Acta Med Scand Suppl. 1982; 668: 49-59.
18.Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999; 131(1): 7-13.
19.Iribarren C, Folsom AR, Eckfeldt JH, McGovern PG, Nieto FJ. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis Risk in Communities. Ann Epidemiol. 1996; 6(4): 331-40.
20.Reed DM, MacLean CJ, Hayashi T. Predictors of atherosclerosis in the Honolulu Heart Program. I. Biologic, dietary, and lifestyle characteristics. Am J Epidemiol. 1987; 126(2): 214-25.
21.Ames BN, Cathcart R, Schwiers E, and Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci 1981; 78: 6858–62.
22.Davies KJ, Sevanian A, Muakkassah-Kelly SF, and Hochstein P. Uric acidiron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J .1986; 235:747–754.
23.Nieto FJ, Iribarren C, Gross MD, Comstock GW, and Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000; 148:131–9.
24.De Scheerder IK, van de Kraay AM, Lamers JM, Koster JF, de Jong JW, Serruys PW. Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: potential mechanisms for free radical generation. Am J Cardiol 1991; 68: 392–5.
25.Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ., et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J. 1998; 19: 1814–22.
26.Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005; 16(12): 3553-62.
27.Johnson RJ., et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003; 41(6): 1183-90.
28.Costa F., et al. Intravascular source of adenosine during forearm ischemia in humans: implications for reactive hyperemia. Hypertension. 1999; 33(6): 1453-7
29.Raatikainen MJ, Peuhkurinen KJ, Hassinen IE. Contribution of endothelium and cardiomyocytes to hypoxia-induced adenosine release. J Mol Cell Cardiol. 1994; 26(8): 1069-80.
30.Fredholm BB, Sollevi A. Cardiovascular effects of adenosine. Clin Physiol. 1986; 6(1): 1-21
31.Kroll K, Bukowski TR, Schwartz LM, Knoepfler D, Bassingthwaighte JB Capillary endothelial transport of uric acid in guinea pig heart. Am J Physiol. 1992; 262(2 Pt 2): H420-31.
32.Castelli P, Condemi AM, Brambillasca C, Fundarò P, Botta M, Lemma M, Vanelli P, Santoli C, Gatti S, Riva E Improvement of cardiac function by allopurinol in patients undergoing cardiac surgery. J Cardiovasc Pharmacol. 1995; 25(1): 119-25.
33.Kogure K, Ishizaki M, Nemoto M, Kuwano H, Tatemoto K, Maruyama Y, et al. Evaluation of serum uric acid changes in different forms of hepatic vascular inflow occlusion in human liver surgeries. Life Sci. 1999; 64(5): 305-13.
34.Mathru M, Dries DJ, Barnes L, Sukhani R, Rooney MW. Tourniquet induced exsanquination in patients requiring lower limb surgery. An ischemia reperfusion model of oxidant and anti oxidant metabolism. Anesthesiology. 1996; 84:14-22
35.Anker SD, Leyva F, Poole-Wilson PA, Kox WJ, Stevenson JC, Coats AJ. Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. Heart. 1997; 78(1): 39-43.
36.Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell JM. Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clin Exp Pharmacol Physiol. 1998; 25(3-4): 175-84.
37.Modan M, Halkin H. Hyperinsulinemia or increased sympathetic drive as links for obesity and hypertension. Diabetes Care. 1991; 14(6): 470-87.
38.Zweier JL, Kuppusamy P, Lutty GA. Measurement of endothelial cell free radical generation: evidence for acentral mechanism of free radical injuryin postischemic tissues. Proc Natl AcadSci. 1988; 85: 4046-50
39.Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction and vasoconstriction. Kidney Int. 2005; 67:1739-42
40.Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VD., et al. Uric acid and inflammatory markers. Eur Heart J. 2006; 27: 1174-81.
41.Ruggiero C, Cherubini A, Miller E, Maggio M, Najjar SS, Lauretani F. et al. Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years. Am J Cardiol. 2007; 100: 115-121
42.Iliesiu A, Campeanu A, Dusceac D Serum uric acid and cardiovascular disease. Maedica (Buchar). 2010; 5(3): 186-92.
43.Hozawa A, Folsom AR, Ibrahim H, Nieto FJ, Rosamond WD, Shahar E, et al. Serum uric acid and risk of ischemic stroke: the ARIC study. Atherosclerosis. 2006; 187:401-407.
44.Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006; 54: 2688-2696.
45.Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Uric Acid and risk of myocardial infarction, stroke and congestive heart failure in 417734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Journal of Internal Medicine. 2009; 226: 558-570.
46.Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R, et al. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens.1994; 8: 677–81.
47.Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med. 1980; 93: 817-821.
48.Puig JG and Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens.1999; 17: 869-72.
49.Fried HP, Till GO, Trentz O, Ward PA. Role of oxygen radicals in tourniquet related ischemia-reperfusion injury of human patients. Klin Wochenschr. 1991; 69: 1109–12.
50.Feig DI, Kang DH, Johnson RG. Uric acid and Cardiovascular Risk, N Engl J Med. 2008; 359: 1811-1821.
51.Lee JE, Kim YG, Choi YO. Serum uric acid Is Associated with Microalbuminuria in Prehypertension. Hypertension. 2006; 47: 962-967.
52.Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal independent mechanism. Hypertension. 2001; 38: 1101-06.
53.M azzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism Am J Physiol Renal Physiol. 2002; 282: 991-997.
54.Watanabe S., Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, et al . Uric acid, hominoid evolution and the pathogenesis of salt-sensitivity. Hypertension. 2002; 40: 355-360
55.Sundström J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence in the Framingham Heart Study. Hypertension. 2005; 45: 28-33.
56.Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and Incidence of Hypertension Among Men Without Metabolic Syndrome. Hypertension. 2007; 49: 298-303.
57.Feig DI, Johnson RJ. Hyperuricemia in childhood essential hypertension. Hypertension. 2003; 42: 247-252.
58.Alper AB Jr, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL. Childhood Uric Acid Predicts Adult Blood Pressure: The Bogalusa Heart Study. Hypertension. 2005; 45: 34-38.
59.I Feig, B Soletsky, RJ Johnson. Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential Hypertension: A Randomized Trial. JAMA. 2008; 300(8): 924-32.
60.Hoeper MM, Hohlfeld JM, Fabel H. Hyperuricaemia in patients with right or left heart failure. Eur Respir J. 1999; 13: 682-685.
61.Campeanu A, Iliesiu A, Nistorescu D. Serum concentration of uric acid in patients hospitalized with chronic heart failure. Heart Failure Congress, Poster Session Berlin. 2010.
62.Lainscak M, von Haehling S, Anker SD. Natriuretic peptides and other biomarkers in chronic heart failure: From BNP, NT-proBNP, and MR-proANP to routine biochemical markers. International Journal of Cardiology. 2009; 3: 303-311.
63.Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, et al. Uric acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging. Circulation. 2003; 107: 1991-97.
64.Pascual-Figal DA, Hurtado-Martínez JA, Redondo B, Antolinos MJ, Ruiperez JA, Valdes M. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail. 2007; 9: 518-524
65.Alimonda AL, Núñez J, Núñez E, Husser O, Sanchis J, Bodí V, Miñana G, et al. Hyperuricemia in acute heart failure. More than a simple spectator? European Journal of Internal Medicine. 2009; 20: 74-9.
66.Ekundayo OJ, Dell'Italia LJ, Sanders PW, Arnett D, Aban I, Love TE, et al. Association between hyperuricemia and incident heart failure among older adults: Apropensity matched study. International Journal of Cardiology. 2010; 142: 279-87.
67.Krishnan E. Hyperuricemia and Incident Heart Failure. Circ Heart Fail. 2009; 2: 556-62
68.Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G. The paradoxical relationship between serum acid uric and cardiovascular disease. Clinica Chimica Acta. 2008; 392: 1-7.
69.Høieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004; 65: 1041-1049.
70.Athyros VG, Elisaf M, Papageorgiou AA .Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Am J Kidney Dis. 2004; 43: 589-599.
71.Farquharson CA, Butler R, Hill A. et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221-226.
72.Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, et al. Impact of oxypurinol in patients with symptomatic heart failure. J Am Coll Cardiol. 2008; 51: 2301-2309.
73.Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, Stevenson JC, Coats AJ. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997; 8: 858–865.
74.Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973–79.
75.Mustard JF, Murphy EA, Ogryzlo MA. Smythe HA. Blood coagulation and platelet economy in subjects with primary gout. Can Med Assoc J. 1963; 89: 1207–11.
76.Johnson WD, Kayser KL, Brenowitz JB, Saedi SF. A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J. 1991; 121: 20–24.
77.Tabayashi K, Suzuki Y, Nagamine S, Ito Y, Sekino Y, Mohri H. A clinical trial of allopurinol (Zyloric) for myocardial protection. J Thorac Cardiovasc Surg. 1991; 101: 713–718.
78.Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104: 2407–2411.
79.Waring WS, Webb DJ, Maxwell SRJ. Effect of local hyperuricemia on endothelial function in the human forearm vascular bed. Br J Clin Pharmacol. 2000b; 49: 511.
80.Kanabrocki EL, Third JL, Ryan MD, Nemchausky BA, Shirazi P, Scheving LE, et al Circadian relationship of serum uric acid and nitric oxide. JAMA. 2000; 283: 2240–41.
81.Santos CXC, Anjos EI, Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys. 1999; 372: 285–294.
82.Abuja PM. Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett. 1999; 446: 305–8.
83.Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM., et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys. 2000; 376: 333-7.
84.Hink HU, Santanam N, Dikalov S, McCann L, Nguyen AD, Parthasarathy S,. et al. Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol. 2002; 22: 1402–8.
85.Maples KR, Mason RP. Free radical metabolite of uric acid. J Biol Chem. 1988; 263: 1709-12.
86.Feig D I, Kang D H, Johnson R J. Uric Acid and Cardiovascular Risk. N Engl J Med. 2008 October 23; 359(17): 1811–1821.
87.George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114: 2508–16.
88.Waring WS, McKnight JA, Webb DJ, Maxwell SR. Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia. 2007; 50: 2572–9.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Joshi M, Sodhi KS, Pandey R, Singh J, Goyal S. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Gulati Deepti1* and Goyal Pallavi2
Affiliation:-
1Senior Lecturer, 2Graduate, Department of Biotechnology, Dolphin (PG) Institute of Biomedical & Natural Sciences, Dehra Dun-248007, Uttarakhand, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Biotechnology, Dolphin (PG) Institute of Biomedical & Natural Sciences, Dehra Dun-248007, Uttarakhand, India
Address reprint requests to
Deepti Gulati,
House No. 5/12/3, Prem Nagar, Dehra Dun, Uttarakhand-248007,India
Article citation: Gulati D, Goyal P. Identification and multiple drug resistance of bacteria Isolated from soil samples collected from pharmaceutical industrial Area. J Pharm Biomed Sci. 2014; 04(11):984-994. Available at www.jpbms.info
ABSTRACT
The present study was aimed to determine Multiple-Drug Resistance among the isolated bacterial populations. The antibiotic sensitivity test was performed against 8 different antibiotics for the 16 bacterial strains isolated from Industrial area, Selaqui, Dehra Dun. All the strains were identified by Gram staining and Biochemical tests. They included; Pseudomonas sp., Bacillus sp., Klebsiella sp., Proteus sp., Staphylococcus sp., Streptococcus sp. and Enterococcus sp. The antibiotics used in the study were Penicillin (10μg), Neomycin (30μg), Cefotaxime (10μg), Rifampicin (2μg), Streptomycin(10μg), Cotrimoxazole(25μg),Amoxicillin(10μg) and Ciprofloxacin (10μg). Most of the isolates were found to be resistant to Rifampicin and Penicillin. 62.5% of the isolates were found to be resistant to Rifampicin, 56.25% to Penicillin, 12.5% to Neomycin, 12.5% to Cotrimoxazole, 6.25% to Streptomycin, 6.25% to Amoxycillin and 6.25% to Ciprofloxacin. None of the isolates was found to be resistant to Cefotaxime. The results of the study showed Rifampicin to be the least effective medicine and Cefotaxime to be the most effective medicine.
KEYWORDS: Antibiotic sensitivity; Multiple-drug resistance; Pharmaceutical effluent.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
REFERENCES
1.Benotti and Etho (2008). Pharmaceuticals as Tracers of Municipal Waste water in Urban Estuaries. (BEN – 117 – 831465).
2. Roth, C; Dong, Z., Senn, D., Maclead, M. & Shine, J. (2005). Transport and Fate of Selected Priority Pharmaceuticals in U.S. Harvard University, Boston, MANAGEMENT USA Swiss Federal Institute of Technology, Zurich, Switzerland. (ROT – 117 – 834293).
3.Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs.2009;69 (12): 1555–623.
4.Stix G . An antibiotic resistance fighter. Sci. Am. 2006;294(4): 80–3.
5.Bauer, AW, Kirby WM, Sherris JC and Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am. J. Clin. Pathol. 1966;45: 493-496.
6.DebMandal Manisha, Mandal Shyamapada and Kumar Pal Nishith. Antibiotic resistance prevalence and pattern in environmental bacterial isolates. The open antimicrobial agents’ journal.2011; 3:45-52.
7.Amit Pandey, Afsheen, Firdous Ara, Sudeep Kumar Tiwari. Isolation and characterization of multi drug resistance cultures from waste water. Journal of Pharmaceutical and Biomedical Sciences (J Pharm Biomed Sci). 2011:13(14). Accessed from www.jpbms.info
8.Sahaab Farooq, Ifra Ghori and Faiqa Abdur Rub (2013). “Identification and multiple drug resistance of bacteria, isolated from pharmaceutical industrial effluent (Islamabad, Pakistan)”. Int J Curr Sci. 2013;6:E 125-132.
9.Chaturvedi Sonal, Chandra Ram and Rai Vibhuti (2008). “Multiple antibiotic resistance patterns of rhizospheric bacteria isolated from Phragmites australis growing in constructed wetland for distillery effluent treatment”. J. Environ. Biol.2008;29(1):117 124.
Copyright © Gulati D,Goyal P. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.